“This collaboration with Scribe complements our robust research efforts across the NK cell therapy spectrum and offers our scientists unique access to engineered CRISPR-based technologies as they strive to deliver off-the-shelf NK cell therapies and novel combination approaches that improve upon the first generation of cell therapies. Blood cancersįrank Nestle, chief scientific officer at Sanofi, said: “We are pushing the boundaries of science by developing a diverse range of next-generation therapies based on natural killer (NK) cells, which could have broad applications across solid tumors and blood cancers. Under the terms of the agreement, Scribe will receive $25 million in upfront payment and be eligible to potentially receive more than $1 billion in payments based on development and commercial milestones, as well as tiered royalties on net future sales on any products that may result from this research agreement. “Scribe is proud to expand the use of our XE CRISPR technologies with the team at Sanofi, whose commitment to deep scientific rigor and clinical development experience will enable the rapid advancement of novel ex vivo cell therapies for patients in need.” Next-generation therapies Scribe Therapeutics’ gene editing technologiesīenjamin Oakes, co-founder and CEO of Scribe Therapeutics, said: “We’re pleased to provide Sanofi with access to Scribe’s proprietary and enhanced gene editing technologies for use in ex vivo oncology applications distinct from our current pipeline. The founders set out with an intention to engineer the very best CRISPR platform, with a bold leap from CRISPR discovery to CRISPR design. The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies. ALAMEDA, Calif.-(BUSINESS WIRE)-Mar 31, 2023- Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days Business Maryville Daily Forum Skip to main content Thank you for reading Please purchase a subscription to read our premium content. Scribe Therapeutics presents a solution unique amongst CRISPR companies to address these limitations: it was built from the ground up to take a tech approach.
Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s expanding pipeline of NK cell therapeutics for oncology. To learn more about Scribe’s mission to engineer the future of genetic medicine, visit Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. In 2020, Scribe announced their research collaboration with Biogen to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS). He has contributed to over 25 publications and patent applications across. “Scribe’s custom-designed CRISPR platforms, molecules, and delivery technologies are overcoming the technical hurdles that challenge many genetic targeting technologies and we are thrilled to continue to drive forward a new era of truly transformative genetic medicines.” Ben Oakes is Co-founder, President, & CEO Scribe Therapeutics. “At Scribe, we continue to push the boundaries of molecular engineering to fulfill the profound promise of CRISPR-based therapeutics and are pleased to have our collaborators at Biogen continue to support and expand our collaboration towards this goal,” said Benjamin Oakes, CEO and co-founder of Scribe Therapeutics.
The expanded collaboration further validates Scribe’s position as a leading organization driving the development of novel CRISPR-based therapeutics that treat the underlying cause of disease. (Nasdaq:BIIB) has exercised an option for an additional disease target in gene therapy as part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based medicines. ALAMEDA, Calif.-( BUSINESS WIRE)-Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, announced Biogen Inc.
0 kommentar(er)
